John Renger
Chief Tech/Sci/R&D Officer at CEREVEL THERAPEUTICS HOLDINGS, INC.
Net worth: 269 260 $ as of 2024-03-30
Profile
Presently, John Renger is Chief Scientific Officer of Cerevel Therapeutics Holdings, Inc. In the past Dr. Renger was Associate Vice President at Merck & Co., Inc. and Vice President-Research & Development at Imbrium Therapeutics LP. He received a doctorate and an undergraduate degree from the University of Iowa.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-06 | 6,370 ( 0.00% ) | 269 260 $ | 2024-03-30 |
John Renger active positions
| Companies | Position | Start |
|---|---|---|
| CEREVEL THERAPEUTICS HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 2019-04-30 |
Former positions of John Renger
| Companies | Position | End |
|---|---|---|
Purdue Pharma LP
 Purdue Pharma LP Pharmaceuticals: MajorHealth Technology Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT. | Corporate Officer/Principal | 2018-03-31 |
| MERCK & CO., INC. | Corporate Officer/Principal | 2016-07-31 |
Imbrium Therapeutics LP
 Imbrium Therapeutics LP Pharmaceuticals: MajorHealth Technology Part of Purdue Pharma LP, Imbrium Therapeutics LP is a clinical-stage biopharmaceutical company based in Stamford, CT. The private company is dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. Imbrium is pursuing oncology chemotherapeutics, treatments for disorders of the central nervous system, and non-opioid approaches to the management of pain. The company strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians, and health systems worldwide. Imbrium has built a robust and diversified pipeline of investigational drug candidates, and actively collaborates with industry and academic partners to identify and advance future impactful medicines. | Chief Tech/Sci/R&D Officer | - |
Training of John Renger
| University of Iowa | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| CEREVEL THERAPEUTICS HOLDINGS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Purdue Pharma LP
Purdue Pharma LP Pharmaceuticals: MajorHealth Technology Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT. | Health Technology |
Imbrium Therapeutics LP
Imbrium Therapeutics LP Pharmaceuticals: MajorHealth Technology Part of Purdue Pharma LP, Imbrium Therapeutics LP is a clinical-stage biopharmaceutical company based in Stamford, CT. The private company is dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. Imbrium is pursuing oncology chemotherapeutics, treatments for disorders of the central nervous system, and non-opioid approaches to the management of pain. The company strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians, and health systems worldwide. Imbrium has built a robust and diversified pipeline of investigational drug candidates, and actively collaborates with industry and academic partners to identify and advance future impactful medicines. | Health Technology |
- Stock Market
- Insiders
- John Renger
